| Name | Title | Contact Details |
|---|
Rallybio is a privately-held development-stage biotechnology company incorporated in January 2018. Our ambition is to create a leading biotechnology organization that transforms the lives of patients with devastating disease, built around people with an outstanding track record in pharmaceutical research and development. We will identify and accelerate the development of highly-promising drug candidates that have strong biological rationales and that can be addressed using the well-validated therapeutic modalities of small molecules, engineered proteins, and antibodies. A part of the Technology Incubation Program at the University of Connecticut in Farmington, CT, we continue to expand our drug acquisition and development capabilities through the assembly of a team of individuals with an outstanding track record in pharmaceutical research, development, and a strong understanding of the financial components of the industry. This seasoned team enables us to search for and evaluate assets using a series of robust clinical and commercial filters that will allow us to identify and acquire a portfolio of high-quality small molecule and protein-based assets in the late discovery to early clinical stages of drug development. Named by FierceBiotech as one of its “Fierce 15” Biotech Companies of 2018, the company was recognized as being among “the most promising private biotech startups”. Rallybio has earned the support of highly-respected investors in the bioscience sector and announced in April 2018 that it had secured $37.0 million in Series A funding with lead financing from 5AM Ventures, Canaan Partners, and New Leaf Venture Partners, and additional public-sector participation from Connecticut Innovations.
RootPath, Inc. is a Cambridge, MA-based early-stage biotechnology company focusing on next-generation immuno- and cell-therapy.
BC International Corporation is a Dedham, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Axcella is designing and developing AXA Candidates, compositions of endogenous metabolic modulators, or EMMs, engineered in distinct ratios, designed to target and maximize the fundamental role that EMMs play in regulating multiple metabolic functions. Axcella`s AXA Candidates are generated from its proprietary, human-focused AXA Development Platform. Axcella believes its expertise and capabilities in EMMs position it to become a preeminent biotechnology company reprogramming metabolism to address a diverse set of complex diseases and support health. Axcella`s AXA Development Platform has already produced a pipeline of product candidates in programs targeting liver, muscle and blood. Axcella was founded by Flagship Pioneering.
Bio Analytical Research Corporation is a New Hyde Park, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.